Did they just beat EPS? NASDAQ:RYAAY, NASDAQ:SMMT, NASDAQ:FSTX, NASDAQ:RKDA

RYANAIR EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:RYAAY)

IS RYANAIR A BUY RIGHT NOW? (NASDAQ:RYAAY)

15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Ryanair in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Ryanair stock.
Ryanair

SUMMIT THERAPEUTICS (NASDAQ:SMMT) EARNINGS INFORMATION (NASDAQ:SMMT)

Summit Therapeutics last released its earnings data on May 17th, 2021. The reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.04. Summit Therapeutics has generated $0.00 earnings per share over the last year.

IS SUMMIT THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:SMMT)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Summit Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
Summit Therapeutics

F-STAR THERAPEUTICS (NASDAQ:FSTX) EARNINGS INFORMATION (NASDAQ:FSTX)

F-star Therapeutics last announced its earnings data on May 16th, 2021. The reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.08. F-star Therapeutics has generated ($5.88) earnings per share over the last year. F-star Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 9th, 2021 based off prior year’s report dates.

IS F-STAR THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:FSTX)

5 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for F-star Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” F-star Therapeutics stock.
F-star Therapeutics

ARCADIA BIOSCIENCES (NASDAQ:RKDA) EARNINGS INFORMATION (NASDAQ:RKDA)

Arcadia Biosciences last announced its quarterly earnings data on May 16th, 2021. The basic materials company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.46. Arcadia Biosciences has generated ($3.37) earnings per share over the last year. Arcadia Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 12th, 2021 based off prior year’s report dates.

IS ARCADIA BIOSCIENCES A BUY RIGHT NOW? (NASDAQ:RKDA)

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Arcadia Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Arcadia Biosciences stock.
Arcadia Biosciences